Health & Medicine | Jan 8, 2026 | 11 min read | By Bryan White

The Long Tail of COVID: The XFG Variant, Microclots, and the Economic Fallout

Biology * Public Health * DNA

Introduction: The Endemic Respiratory Landscape of Winter 2025-2026

As the United States moves through the winter of 2025-2026, the public health trajectory of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has transitioned from acute pandemic mortality waves into a persistent endemic burden. Defined by rapid viral evolution, seasonal surges, and cumulative chronic morbidity from Post-Acute Sequelae of SARS-CoV-2 (PASC, or Long COVID), the virus continues to strain clinical and economic infrastructure.

Current epidemiological surveillance shows SARS-CoV-2 co-circulating alongside resurgent Influenza A (H3N2) subclade K and steady levels of Respiratory Syncytial Virus (RSV).[1][2] While pediatric RSV immunizations have stabilized infant admissions, the Centers for Disease Control and Prevention (CDC) projects peak weekly COVID-19 hospitalization rates of 6.7 to 9.5 per 100,000 population in January 2026, with effective reproductive numbers (Rt > 1) indicating active epidemic growth across 37 U.S. states.[1][8]

Virological Evolution: Ascendance of the XFG Lineage

Genomic surveillance in January 2026 identifies the XFG lineage as the dominant variant nationwide (61% of sequenced cases), alongside sublineages XFG.14.1 (15%) and XFG.1 (5%), displacing earlier JN.1, KP.2, and LP.8.1 strains, with XFG and sublineage XFG.1.1 persisting into fall 2026 alongside emerging SW.2 and RW.1.1 lineages.[3][6] Descended from the JN.1 phylogenetic umbrella, XFG carries key Spike protein amino acid substitutions -- specifically A475V and N487D -- that confer substantial evasion of neutralizing antibody responses in populations with hybrid immunity from prior infection and vaccination.[4][5]

Antigenic cartography demonstrates significant antigenic distance between XFG and the LP.8.1 lineage targeted by the 2025-2026 monovalent mRNA vaccine formulation, compounded by immune imprinting toward ancestral epitopes.[6][7][35] Although LP.8.1 boosters continue to mitigate severe acute hospitalization, ongoing genetic drift reduces protection against symptomatic infection and transmission.[1][7]

| Variant Lineage | | US Prevalence (Jan 2026) | | Virological & Antigenic Characteristics |

| XFG | | 61% | | Dominant US strain; Spike A475V and N487D mutations drive humoral immune escape while preserving ACE2 affinity.[3][5] |

| XFG.14.1 / XFG.1 | | 15% / 5% | | Circulating XFG sublineages with comparable antigenic escape profiles.[3] |

| NB.1.8.1 | | <5% (Monitored) | | Combines high ACE2 binding affinity with strong humoral immune evasion; monitored for future growth.[5] |

| LP.8.1 | | Declining | | Target strain of the 2025-2026 vaccine formulation; displaced by XFG.[6][7] |

| BA.3.2 | | Low | | Outcompeted by XFG and NB.1.8.1 due to lower relative fitness.[5] |

Epidemiology and Pathophysiology of Long COVID (PASC)

While acute mortality has declined, Long COVID has emerged as a cumulative mass-disabling condition. Global meta-analyses through 2025 estimate a pooled post-infection PASC prevalence of up to 36%, while U.S. electronic health record (EHR) cohorts document clinical diagnosis rates of 10% to 26% in adults and ~4% in children.[9][11] Crucially, reinfection carries a linear dose-response hazard: longitudinal tracking shows PASC prevalence rising from 9.1% after a first infection to 30.7% after three or more infections in unvaccinated cohorts, and from 10.6% to 25.4% in vaccinated cohorts.[12]

| PASC Risk Factor | | Association / Metric | | Epidemiological & Clinical Insight |

| Biological Sex | | OR 1.56 (Female) | | Higher female susceptibility linked to heightened innate and autoimmune responses.[10] |

| Vaccination Status | | OR 2.09 (Unvaccinated) | | Unvaccinated status doubles PASC risk, though breakthrough infections retain cumulative risk.[10][12] |

| Cumulative Reinfections | | 25.4% - 30.7% (3 Infections) | | Each subsequent SARS-CoV-2 infection compounds chronic sequelae probability.[12] |

| Cardiovascular Sequelae | | HR 6.11 (Myocarditis) / HR 3.12 (Thrombosis) | | Persistent vascular endotheliitis and myocardial inflammation up to 12 months post-infection.[20][21] |

By 2026, translational research has linked PASC symptom clusters to three core biological mechanisms plus downstream organ injury:

* Viral Reservoirs: Biopsy and autopsy studies demonstrate persistent SARS-CoV-2 RNA and viral proteins within intestinal mucosa, lymph nodes, and central nervous system tissues months after acute clearance, driving chronic cytokine release.[13][14]

* Fibrin Amyloid Microclots: Biochemical studies confirm that amyloidogenic segments of the SARS-CoV-2 Spike protein (specifically Spike685 fibrils) cause fibrinogen to misfold into dense "fibrinaloid" microclots resistant to plasmin fibrinolysis.[15][16] These microclots trap inflammatory molecules and occlude microcapillaries, inducing cellular hypoxia -- starving tissues of oxygen despite normal arterial pulse oximetry -- and driving Post-Exertional Malaise (PEM).[15][17]

* AMPA Receptor Neuroinflammation: Positron Emission Tomography (PET) brain imaging in 2025 identified widespread upregulation of excitatory AMPA receptor density across the cortex of patients with Long COVID "brain fog," linking neuroinflammation and excitotoxicity to measurable executive and memory deficits.[18][19]

* Cardiometabolic Injury: Direct ACE2-mediated pancreatic beta-cell cytotoxicity and IFN- -driven islet Treg disruption have elevated new-onset Type 1 and Type 2 diabetes diagnoses post-infection, alongside doubled rates of thromboembolic events in adults over age 60.[21][22][23]

Therapeutic Pipeline and Macroeconomic Labor Fallout

Clinical trials through 2025-2026 have clarified the therapeutic landscape for PASC. On the preventative front, a UK target trial emulation of over 600,000 patients confirmed findings from the COVID-OUT trial: initiating Metformin within three days of acute COVID-19 diagnosis reduces PASC incidence by 63% to 64% in overweight or obese adults via mTOR viral inhibition and anti-inflammatory modulation.[24][25] Conversely, repurposed treatments suffered clinical setbacks: 15-day and 25-day courses of Paxlovid (nirmatrelvir/ritonavir) in the NIH RECOVER-VITAL phase 2 trial failed to improve established PASC symptoms, while Montelukast showed no benefit for accelerating sustained recovery among acute COVID-19 outpatients in ACTIV-6.[26][27] Active 2026 trials now target root pathophysiology, including 150 kHz low-intensity focused ultrasound (LIFU) for microclot lysis, PridCor Therapeutics' Phase 2 combination antiviral regimen (IMC-2), stellate ganglion blocks for dysautonomia, and GLP-1 receptor agonists.[15][28]

Meanwhile, the socioeconomic toll of untreated PASC continues to distort the U.S. labor market. Brookings Institution and macroeconomic analyses estimate that 2 million to 4 million Americans remain out of the labor force due to Long COVID, shifting the Beveridge Curve outward and generating $170 billion to $230 billion in annual lost wages -- part of an estimated $1 trillion annual global toll and $3.7 trillion long-term U.S. economic burden when accounting for lost quality-adjusted life years (QALYs) and medical expenditures.[29][30][31] Although the Social Security Administration reduced initial disability claim backlogs by 25% in 2025, standard clinical panels still lack routine microclot or viral-reservoir assays, complicating disability adjudication even as updated 2026 CDC and AAPM&R clinical guidelines emphasize symptom validation, energy pacing to prevent PEM, and targeted autonomic management.[32][33][34]

Conclusion: Mitigating Chronic Morbidity in an Endemic Era

The winter of 2025-2026 underscores that endemicity does not equate to clinical benignity. Driven by the immune-evasive XFG lineage, recurring SARS-CoV-2 infections continue to expand the cohort of individuals suffering from persistent viral reservoirs, plasmin-resistant fibrin amyloid microclots, and AMPA-mediated neuroinflammation. Stabilizing both public health and labor force participation requires pairing updated mucosal and broad-spectrum vaccination strategies with acute-phase Metformin prophylaxis and targeted clinical therapeutics capable of reversing the microvascular and neurological drivers of Long COVID.

Updates... (Nov 25, 2026): Verified Ref. 8's live CDC CFA publication/update metadata (2026, Nov 20), upgraded four PMC citations (Refs. 13, 14, 23, 27) to their CrossRef-verified primary journal DOIs with exact publication dates and pagination, added exact CrossRef publication dates and volume/issue/page metadata across Refs. 5, 12, 15-19, 21-22, 24, and 31, updated Ref. 32 to its canonical URL, replaced the mismatched acute-phase Paxlovid reference in Ref. 26 with the primary NIH RECOVER-VITAL phase 2 randomized clinical trial (Baden et al., Aug 2026, The Lancet Infectious Diseases, 10.1016/S1473-3099(26)00406-8), clarified that ACTIV-6 (Ref. 27) evaluated Montelukast in acute outpatient COVID-19 rather than established PASC, and normalized HTML markup; previously (Nov 21, 2026) corrected first-author initial

on Westman et al. (2025), upgraded Guo et al. (2025), Fujimoto et al. (2025), Abbad et al. (2025/2026), Hou et al. (2025), Cheng et al. (2025), and Kumar et al. (2026) to published journal DOIs, and added fall 2026 lineage context (XFG.1.1, SW.2, RW.1.1).

References & Primary Sources

* [1] Respiratory Therapy (2025, Aug 31). CDC Predicts Possibility of Higher COVID-19 Hospitalizations for 2025-26 Season. -- https://respiratory-therapy.com/disorders-diseases/infectious-diseases/coronavirus/cdc-higher-covid-19-hospitalizations/

* [2] Advisory Board (2026, Jan 6). Mapped: 'Super flu' variant driving surge in cases, hospitalizations. -- https://www.advisory.com/daily-briefing/2026/01/06/flu-update

* [3] Nebraska Medicine (2026, Sep 1). What COVID-19 variants are going around in September 2026? -- https://www.nebraskamed.com/COVID/what-covid-19-variants-are-going-around

* [4] World Health Organization (WHO) (2025, Jun 25). TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: XFG. -- https://www.who.int/docs/default-source/coronaviruse/25062025_xfg_ire.pdf

* [5] Guo, C., Yu, Y., Liu, J., et al. (2025, Jul). Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1. The Lancet Infectious Diseases, 25(7), e374-e377. -- https://doi.org/10.1016/s1473-3099(25)00308-1

* [6] Pfizer Inc. (2025, Aug 27). Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19. -- https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval

* [7] Abbad, A., Lerman, B., Ehrenhaus, J., et al. (2025, Nov 25; issue Jan 14, 2026). Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination. mBio, 17(1), e02901-25. -- https://doi.org/10.1128/mbio.02901-25

* [8] Centers for Disease Control and Prevention (CDC) Center for Forecasting and Outbreak Analytics (2026, Nov 20). Current Epidemic Trends (Based on Rt) for States. -- https://www.cdc.gov/cfa-modeling-and-forecasting/rt-estimates/index.html

* [9] Hou, Y., Gu, T., Ni, Z., Shi, X., et al. (2025, Aug 30). Global Prevalence of Long COVID, Its Subtypes, and Risk Factors: An Updated Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 12(9), ofaf533. -- https://doi.org/10.1093/ofid/ofaf533

* [10] CIDRAP, University of Minnesota (2025, Sep 9). Studies show how common long COVID is globally and in teens. -- https://www.cidrap.umn.edu/covid-19/studies-show-how-common-long-covid-globally-and-teens

* [11] NIH RECOVER Initiative (2025, Jun 4). RECOVER Research Update: June 2025. -- https://recovercovid.org/news/recover-research-update-june-2025

* [12] Ar valo-Genicio, A., Garc a-Arqu , M. C., Gragea-Nocete, M., et al. (2025,

Aug 26). Long COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium in the Metropolitan Area of Barcelona: Persistent and Transient Symptoms. Vaccines, 13(9), 905. -- https://doi.org/10.3390/vaccines13090905

* [13] da Silva, M. D., da Silva, T. S., Mendes, C. G., et al. (2025, Jun 18). Advances in Understanding Long COVID: Pathophysiological Mechanisms and the Role of Omics Technologies in Biomarker Identification. Molecular Diagnosis & Therapy, 29(5), 617-636. -- https://doi.org/10.1007/s40291-025-00792-8

* [14] Prakash, S., Karan, S., Lekbach, Y., et al. (2025, Sep 27). Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID. Viruses, 17(10), 1310. -- https://doi.org/10.3390/v17101310

* [15] Rasouli, R., Hartl, B., & Konecky, S. D. (2025, Jun 30). Low-intensity ultrasound lysis of amyloid microclots in a lab-on-chip model. Frontiers in Bioengineering and Biotechnology, 13, 1604447. -- https://doi.org/10.3389/fbioe.2025.1604447

* [16] Westman, H., Hammarstr m, P., & Nystr m, S. (2025, Nov 26). SARS-CoV-2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis. Biochemistry, 64(24), 4818-4829. -- https://doi.org/10.1021/acs.biochem.5c00550

* [17] Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022, Feb 23). A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal, 479(4), 537-559. -- https://doi.org/10.1042/BCJ20220016

* [18] Fujimoto, Y., Abe, H., Eiro, T., et al. (2025, Oct 1). Systemic increase of AMPA receptors associated with cognitive impairment of long COVID. Brain Communications, 7(5), fcaf337. -- https://doi.org/10.1093/braincomms/fcaf337

* [19] Serafim, A. D. P., et al. (2025, Sep 11). Persistence of Cognitive Difficulties in Adults Three Years After COVID-19 Infection. COVID, 5(9), 153. -- https://doi.org/10.3390/covid5090153

* [20] Mount Sinai Health System (2025, May 6). Long COVID May Cause Long-Term Changes in the Heart and Lungs and May Lead to Cardiac and Pulmonary Diseases. -- https://www.mountsinai.org/about/newsroom/2025/long-covid-may-cause-long-term-changes-in-the-heart-and-lungs-and-may-lead-t

* [21] Zhang, T., Li, Z., Mei, Q., Walline, J. H., et al. (2025, Jan 29). Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 12, 1450470. -- https://doi.org/10.3389/fcvm.2025.1450470

* [22] El-Naas, A., Hamad, O., Nair, S., et al. (2025, Jul 14). New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review. Emerging Microbes & Infections, 14(1), 2492211. -- https://doi.org/10.1080/22221751.2025.2492211

* [23] Shitaye, G., Getie, M., Mekonnen, Z., et al. (2025, Dec 18). Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views. Frontiers in Endocrinology, 16, 1737894. -- https://doi.org/10.3389/fendo.2025.1737894

* [24] Chaichana, U., Man, K. K. C., Ju, C., et al. (2025, Sep 1). Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight

or Obese: A Population-based Retrospective Cohort Study. Clinical Infectious Diseases, 82(3), e423-e432. -- https://doi.org/10.1093/cid/ciaf429

* [25] CIDRAP, University of Minnesota (2025, Sep 2). Metformin may reduce risk of long COVID by 64% in overweight or obese adults. -- https://www.cidrap.umn.edu/covid-19/metformin-may-reduce-risk-long-covid-64-overweight-or-obese-adults

* [26] Baden, L. R., Shah, N. S., Liu, S. T. H., Cohen, J., et al. (2026, Aug). Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. -- https://doi.org/10.1016/S1473-3099(26)00406-8

* [27] Rothman, R. L., Stewart, T. G., Mourad, A., et al. (2024, Oct 18). Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Network Open, 7(10), e2439332. -- https://doi.org/10.1001/jamanetworkopen.2024.39332

* [28] PridCor Therapeutics / BioSpace (2026, Jan 7). PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program. -- https://www.biospace.com/press-releases/pridcor-therapeutics-advances-shield-study-through-dual-regulatory-and-scientific-mileston

* [29] Brookings Institution (2022, Aug 24). New data shows long Covid is keeping as many as 4 million people out of work. -- https://www.brookings.edu/articles/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/

* [30] CIDRAP, University of Minnesota (2025, Nov 24). Long COVID takes $1 trillion global economic toll each year, analysis suggests. -- https://www.cidrap.umn.edu/covid-19/long-covid-takes-1-trillion-global-economic-toll-each-year-analysis-suggests

* [31] Bansal, A. (2025, Nov 21). Economic burden of long COVID: macroeconomic, cost-of-illness and microeconomic impacts. npj Primary Care Respiratory Medicine, 35(1), 53. -- https://doi.org/10.1038/s41533-025-00460-8

* [32] Hiller Comerford Injury & Disability Law (2026, Jul 9). Social Security Disability (SSD) Wait Times: Updated Study. -- https://www.hillercomerford.com/ssd-wait-times-case-study/

* [33] U.S. Social Security Administration (2023, Jun). Long COVID: A Guide for Health Professionals on Providing Medical Evidence for Social Security Disability Claims (EN-64-128). -- https://www.ssa.gov/disability/professionals/documents/EN-64-128.pdf

* [34] Cheng, A. L., Herman, E., Abramoff, B. A., Anderson, J. R., et al. (2025, Apr 22). Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement. PM&R, 17(6), 684-708. -- https://doi.org/10.1002/pmrj.13397

* [35] Kumar, S., Lai, L., Ellis, M. L., Patel, A., et al. (2026, Aug 26; issue Sep 22, 2026). Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses. Journal of Virology, 100(9), e00749-26. -- https://doi.org/10.1128/jvi.00749-26